A significant decrease (p < 0.05) in ac4C levels was observed in SLC7A11; however, no significant difference (p > 0.05) was observed in GCLC, MAP1LC3A, and SLC39A8 of Remodelin-treated cancer cells (Figure 7A, Supplementary Figure S9). The gene discussed is MAP1LC3A; the disease is cancer.